<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429194</url>
  </required_header>
  <id_info>
    <org_study_id>90891629</org_study_id>
    <secondary_id>90891629</secondary_id>
    <nct_id>NCT01429194</nct_id>
  </id_info>
  <brief_title>The ACE Follow-up Study</brief_title>
  <official_title>Continuation of Follow-up for Patients Who Were Previously Enrolled in the Clinical Study: &quot;Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity - (Protocol 11-03).&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Articulating Circular Endoscopic (ACE) Stapler is an investigational system using
      endoscopic guidance to trans-orally place plications in the stomach in obese subjects to
      reduce volume and expansion of the fundus and greater curve to abate hunger as part of a
      supervised weight reduction program.

      The primary objective of this study is to perform an evaluation of the safety of the
      plication procedure.

      The secondary objective of this study is to evaluate the preliminary efficacy of the ACE
      Stapler for the treatment of obesity over a 24 month follow-up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was originally sponsored by BaroSense, Inc (protocol 11-03). 69 subjects were
      enrolled and treated as part of the study at 6 centers in 4 countries outside the United
      States. On April 30, 2013 BaroSense Inc went out of business and the study was terminated
      with all participating centers' Ethics Committees. At the point of study termination, all
      patients were in the middle of post procedure follow-up.

      Boston Scientific has since acquired the technology and study and will re-initiate follow-up
      to 24 months in order to collect data to support the original safety and efficacy endpoints
      of the protocol. Only the 69 subjects previously enrolled and treated in BaroSense's protocol
      11-03 will be eligible for participation in the Boston Scientific continued follow-up study
      (&quot;The ACE Follow-up Study&quot; protocol 90891629). The Boston Scientific protocol will be
      approved by participating centers' Ethics Committees and patients who choose to participate
      in The ACE Follow-up Study will need to sign a new, Ethics Committee Approved, informed
      consent form.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Enrollment through 24 months post-procedure.</time_frame>
    <description>The primary safety analysis will assess the occurrence and procedure relatedness of the following events:
Adverse Events (AE)
Adverse Device Effects (ADE)
Serious Adverse Events (SAE)
Unanticipated Adverse Device Effects (UADE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent excess weight loss</measure>
    <time_frame>Procedure through 24 months post-procedure</time_frame>
    <description>Percent excess weight loss (%EWL), defined as: (preoperative weight-current weight)/(preoperative weight - ideal weight) *100, where ideal weight is the weight that would correspond to a BMI of 25 based on the subject's height.
Relative to weight at the procedure visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total weight lost (kg) and percent weight lost</measure>
    <time_frame>Procedure through 24 months post-procedure</time_frame>
    <description>Relative to weight at the procedure visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI) and percent change in BMI</measure>
    <time_frame>Procedure through 24 months post-procedure</time_frame>
    <description>Relative to BMI at the procedure visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Procedure through 24 months post-procedure</time_frame>
    <description>Relative to to waist circumference at the procedure visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in co-morbid disease(s)</measure>
    <time_frame>Enrollment through 24 months post-procedure</time_frame>
    <description>Including but not limited to, improvement in vital signs and/or laboratory values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life</measure>
    <time_frame>Enrollment through 24 months post-procedure</time_frame>
    <description>As reported on the SF-36 Quality of LIfe Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Feelings of Satiety</measure>
    <time_frame>Enrollment through 24 months post-procedure</time_frame>
    <description>As reported on the TFEQ-R18 Three Factor Eating Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>ACE procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE procedure for the treatment of obesity</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ACE Stapler</intervention_name>
    <description>The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.</description>
    <arm_group_label>ACE procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject, male or female, is age 18 to 50 years of age.

          2. Subject must be able to understand and be willing to sign an informed consent
             document.

          3. Subject must be willing and able to participate in all aspects of the study and agree
             to comply with all study requirements for the duration of the study. This includes
             availability of reliable transportation and sufficient time to attend all follow-up
             visits.

          4. Subject has a BMI of 40 - 45 or 30 to 39.9 plus one or more co-morbid diseases
             expected to improve with weight loss, including but not limited to hypertension,
             dyslipidemia, obstructive sleep apnea, or diabetes mellitus.

          5. Subject must be fully ambulatory, without chronic reliance on walking aids such as
             crutches, walkers or a wheelchair.

          6. Subject must be of sufficient and stable medical health, as evaluated by the Principal
             Investigator.

          7. Subject must have a primary care physician that will manage the subject for any
             co-morbid conditions throughout the study.

          8. Subject must have failed standard obesity therapy of diet, exercise, behavior
             modification, and pharmacologic agents either alone or in combination, as assessed by
             an interview with a member of the study team at baseline.

          9. Subject agrees to refrain from any type of reconstructive surgery that may affect body
             weight such as mammoplasty or abdominal lipoplasty or liposuction, during the trial.

        Exclusion Criteria:

          1. Subject has history of/or signs and/or symptoms of gastro-duodenal ulcer disease.

          2. Subject has poorly controlled diabetes as indicated by the lack of stable diabetes
             medications and doses over the last month, or has a history of diabetes for greater
             than 10 years.

          3. Subject has had significant weight loss in the last 3 months, or between baseline and
             the study procedure.

          4. Subject has a history or is diagnosed with eating disorders.

          5. Subject has history of peptic ulcer and tests positive for H. pylori, unless treated
             before the procedure.

          6. Subject has symptomatic congestive heart failure, cardiac arrhythmia or unstable
             coronary artery disease.

          7. Subject has pre-existing respiratory disease such as chronic obstructive pulmonary
             disease (COPD), pneumonia or cancer.

          8. Subject has significant esophageal disease including Zenker's diverticulum, grade 3-4
             reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal
             diverticulum, dysphagia, achalasia, or symptoms of dysmotility.

          9. Subject is observed during EGD to have heavily scarred, malignant or poor
             quality/friable tissue in areas of the stomach where plications are to be placed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Biron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Institute of Cardiology and Pulmonary Medicine of Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Aleman / Programa de Unidades Bari√°tricas</name>
      <address>
        <city>Autonoma de Bueno Aires</city>
        <zip>CP 1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Mendoza / Clinica Quirugica S. A.</name>
      <address>
        <city>Mendoza</city>
        <zip>290</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Institute of Cardiology and Pulmonary Medicine of Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64234</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>110AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight Loss</keyword>
  <keyword>Trans-oral Endoscopic Procedure</keyword>
  <keyword>Gastric Plication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

